Revenue Breakdown
Composition ()
No data
Revenue Streams
Bausch + Lomb Corp (BLCO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Devices, accounting for 37.8% of total sales, equivalent to $484.00M. Other significant revenue streams include OTC and Pharmaceuticals. Understanding this composition is critical for investors evaluating how BLCO navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, Bausch + Lomb Corp maintains a gross margin of 54.88%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 6.25%, while the net margin is -1.95%. These profitability ratios, combined with a Return on Equity (ROE) of -4.69%, provide a clear picture of how effectively BLCO converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BLCO competes directly with industry leaders such as SHC and BRKR. With a market capitalization of $6.02B, it holds a significant position in the sector. When comparing efficiency, BLCO's gross margin of 54.88% stands against SHC's 56.04% and BRKR's 46.44%. Such benchmarking helps identify whether Bausch + Lomb Corp is trading at a premium or discount relative to its financial performance.
